La Roche-Posay Backs the Next Generation of Dermatology Research

In beauty, scientific authority is often compressed into a phrase on a carton: clinically tested, dermatologist recommended, proven by research. La Roche-Posay’s Young Investigator Grant programme looks beyond that familiar language to the slower, less visible work from which meaningful evidence is built.

The brand has now named the publicly listed recipients of its 2025 US grants and opened the next funding cycle for dermatologists at the beginning of their research careers. A combined $50,000 was awarded across projects spanning skin-cancer detection, hidradenitis suppurativa, surgical education, rural access to care, quality-of-life measurement and new approaches to skin resurfacing.

It is a relatively modest pool beside the immense cost of pharmaceutical development or a multicentre clinical trial. Yet early research funding can occupy an important position: allowing an investigator to test an idea, gather preliminary evidence and establish whether a larger study deserves to follow. For a skincare name whose identity rests heavily upon dermatological credibility, that support is also a more substantive expression of scientific positioning than another campaign built around the aesthetics of the laboratory.

Twenty years of supporting emerging investigators

La Roche-Posay describes the US Young Investigator Grant as entering its 20th year. The programme is intended for licensed dermatologists, including residents, fellows and practitioners within their first five years following residency. The selected work must centre on clinical research rather than community-service activity alone.

The 2025 recipients were recognised during the American Academy of Dermatology Annual Meeting in Denver, held from 27 to 31 March 2026. The setting matters. The AAD meeting is one of the specialty’s principal professional gatherings, placing the grants within a clinical and academic environment rather than presenting them as conventional beauty-industry prizes.

The programme forms part of a longer international history of research support associated with La Roche-Posay. Its global research-grant platform says more than 200 grants and prizes have been awarded since 1995, with the broader international scheme focusing particularly on how skin conditions affect everyday wellbeing.

A portfolio shaped by practical questions

The seven researchers currently named on La Roche-Posay’s official US recipient page illustrate the breadth of contemporary dermatology. Their proposals do not converge upon a single fashionable ingredient or condition. Instead, they approach the skin through surgery, imaging, education, access to care, psychological experience and treatment design.

Dr Junqian Zhang’s work concerns the development and evaluation of a translucent suture pad designed to improve training in dermatologic surgery. Dr Leonardo Tjahjono is studying a combined approach to active Hurley stage II and III hidradenitis suppurativa, bringing biologic treatment and deroofing surgery together without interrupting biologic therapy. The George Washington Medical Faculty Associates has separately confirmed Tjahjono’s selection and the project’s focus on hidradenitis suppurativa.

Dr Matthew Draelos is investigating topical chemical probes that could enable fluorescence-based detection and surgical management of non-melanoma skin cancer across different skin phototypes. Dr Miguel Angel Aristizabal Torres is developing a transplant-specific quality-of-life module for solid-organ transplant recipients affected by keratinocyte carcinoma.

Elsewhere, Dr Misty Eleryan’s proposed hybrid of teledermatology and mobile care addresses the detection and treatment of skin cancer in rural communities. Dr Rohan Shah’s trauma-informed project explores laser therapy and skin-barrier science in support of survivors of human trafficking, while Dr William Lewis is examining fractional cryotherapy for resurfacing and the modulation of pigmentation.

Where clinical evidence meets lived experience

Collectively, the projects offer a useful correction to the idea that dermatological innovation is defined only by a new molecule or device. Better medicine can also emerge from improved teaching tools, more appropriate outcome measures, thoughtful combinations of existing interventions and systems that bring specialist expertise to people who cannot readily reach it.

Quality of life is especially significant in dermatology. Skin disease may be physically painful, visible to others and deeply entangled with confidence, work, sleep and social participation. La Roche-Posay’s international grant programme explicitly places patient wellbeing at its centre, supporting research into conditions including atopic dermatitis, psoriasis, autoimmune blistering disease and chronic pruritus. Its 2025 global recipients are separate from the US Young Investigator cohort, but the two initiatives share an emphasis on consequences extending beyond symptoms alone.

That philosophy is evident in the US projects concerning transplant recipients and survivors of trafficking. Neither treats the patient as a purely biological subject. Each recognises that useful research must sometimes measure dignity, access, confidence and the practical experience of receiving care alongside conventional clinical outcomes.

The value — and limits — of brand-funded research

Luxury and prestige beauty increasingly trade upon medical language. Consumers are invited to value formulation precision, laboratory provenance and professional endorsement as they might once have valued rarity alone. This makes support for independent-minded early-career research especially relevant: it redirects a portion of a brand’s scientific narrative towards questions whose value is not confined to selling a finished product.

The arrangement should nevertheless be understood clearly as industry funding. La Roche-Posay appoints the scientific committees and requires grant support to be acknowledged in resulting publications and presentations. Its published rules state that the awards are restricted to the proposed primary research and that projects must comply with applicable ethical, patient-safety, consent and data-privacy requirements. Animal-testing projects are excluded.

Funding alone does not validate a hypothesis, guarantee publication or establish that an intervention is effective. Those judgements depend upon study design, execution, peer review and, where appropriate, replication. The importance of a young-investigator award lies earlier in the process: it creates room for a credible question to be pursued.

Applications open for the next US cycle

For the 2026 cycle, La Roche-Posay is offering a combined funding pool of up to $50,000. Applicants must be US-based dermatology residents, fellows, licensed dermatologists or practitioners no more than five years beyond residency. Proposals are to be assessed for the importance and originality of the research, methodological rigour and feasibility, the investigator’s expertise and resources, and the project’s potential future impact.

The application requires a clinical research plan of no more than eight pages, a budget and curriculum vitae, a letter of support from a mentor or chief of dermatology, and an affidavit addressing prior funding. The public application page gives a deadline of 1 November 2026, with recipients expected to be notified by February 2027.

La Roche-Posay says the next recipients are expected to be recognised at the American Academy of Dermatology Annual Meeting in San Francisco. The AAD independently lists that meeting for 19 to 23 March 2027.

The most persuasive form of scientific luxury is not the appearance of expertise but the patient cultivation of it. By backing dermatologists while their ideas are still becoming studies, La Roche-Posay places part of its reputation behind a process whose rewards may be gradual, uncertain and far more valuable than a seasonal launch.

For the researchers, the grants offer an opening rather than a conclusion. For the beauty industry, they provide a reminder that clinical credibility is earned not only through the evidence attached to products, but through sustained investment in the people asking what better skin care — and better dermatological care — might become.

Imagery disclaimer

All imagery rights remain with their respective owners, photographers and licensors. Simply Luxury will amend crediting or remove material promptly upon request.